抗血管内皮生长因子治疗不同区域早产儿视网膜病变的临床效果

Clinical effect of anti-vascular endothelial growth factor on retinopathy of premature infants in different regions

  • 摘要:
      目的  探讨抗血管内皮生长因子(VEGF)治疗不同区域早产儿视网膜病变的临床效果。
      方法  回顾性分析200例早产儿视网膜病变患儿的临床资料, 根据病变区域分为A组(Ⅰ区, 125例,232眼)、B组(Ⅱ区, 75例, 138眼)。2组均经抗VEGF药物治疗,比较2组疗效。
      结果  A组首次治疗有效率64.66%, 显著低于B组75.36%(P < 0.05); A组二次治疗有效率71.95%, 显著低于B组94.12%(P < 0.05); A组并发症发生率为4.00%, 与B组2.67%相比无显著差异(P>0.05)。
      结论  早产儿视网膜病变Ⅰ区、Ⅱ区病变采用抗VEGF治疗均安全、有效,但Ⅰ区首次治疗有效率低。

     

    Abstract:
      Objective  To investigate the clinical effect of anti-vascular endothelial growth factor (VEGF) in the treatment of retinopathy of premature infants in different regions.
      Methods  Clinical data of 200 premature infants with retinopathy in our hospital were retrospectively analyzed, and these patients were divided into group A (Ⅰ district, 125 cases with 232 eyes) and group B (Ⅱ district, 75 cases with 138 eyes) according to the lesion areas. The clinical efficacy was compared after anti-VEGF treatment.
      Results  The response rates of initial treatment, and secondary treatment of group A were 64.66%, 71.95%, respectively, which were lower than 75.36%, 94.12%, respectively, in group B (P < 0.05). The incidence of complications was 4.00% in group A and 2.67% in group B, but no significant difference was seen between two groups(P>0.05).
      Conclusion  VEGF treatment for premature infants with retinopathy in Ⅰ, Ⅱ lesions is safe in treatment and has better curative efficacy, but therapeutic efficacy in area Ⅰ is lower.

     

/

返回文章
返回